An Update on Animal Models of Autoimmune Hepatitis: Are we There Yet?

Author(s): Urs Christen, Edith Hintermann

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 18 , 2015

Become EABM
Become Reviewer
Call for Editor


Autoimmune hepatitis is characterized by a progressive destruction of the liver parenchyma and a chronic fibrosis. Although the major targets of this autoimmune-mediated disease have been identified more than two decades ago, the current treatment of autoimmune hepatitis is still based on traditional therapies including a glucocorticoid treatment. One reason for this impasse is the limited availability of reliable animal models that reflect the clinical features of autoimmune hepatitis and allow for the identification of critical factors driving the autoimmune destruction and the evaluation of innovative therapies. However, the status of the liver as an immune privileged organ harbouring many immunosuppressing mechanisms hampers the development of such models. Here we will review the past and present attempts to develop a consistent animal model for autoimmune hepatitis.

Keywords: Animal model, CYP2D6, immunotherapy, molecular mimicry, virus infection autoantibodies, liver fibrosis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 30 April, 2015
Page: [2391 - 2400]
Pages: 10
DOI: 10.2174/1381612821666150316121319
Price: $65

Article Metrics

PDF: 52